The June 2020 issue of Antiviral Research journal included a study summary article titled “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro“.
In other words, in a lab, Ivermectin was definitively shown to significantly reduce replication of the Covid-19 virus.
These study highlights were listed:
- Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
- A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.
- Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
- Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
